← Back to patent-cliff list
ABI-6250
Tier C — Watch / tradeABI-6250
Assembly Biosciences Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：NTCP
Indications (approved)：Chronic hepatitis C, 丁型肝炎
Regional status
US
-
2023-10-02
EU
Phase II
2026-08-05
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ABI-6250?
Approved indications include: Chronic hepatitis C, 丁型肝炎.
When does the ABI-6250 patent expire?
No public expiry year is available for ABI-6250 yet; this page updates once verified.
How do I get a quote for ABI-6250 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29